Endocyte, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 74   

Articles published

ECYT 19.14 -0.79 (-3.96%)
price chart
Better Buy: Clovis Oncology, Inc. or Endocyte, Inc?
Biotechs developing treatments for diseases with few therapeutic options can perform well in a variety of situations. This is especially true for developmental stage oncology companies because of the strong demand for new treatments.
Will This Upgrade Help Endocyte (ECYT) Today?  TheStreet.com
Key Market News You Can Trade Off  ETF Daily News (blog)
Related articles »  
Endocyte, Inc. Announces Proposed Offering of Common Stock
WEST LAFAYETTE, Ind., March 25, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) announced today that it is offering to sell 4.5 million shares of its common stock in an underwritten public offering.
Related articles »  
Endocyte (ECYT) Showing Signs Of A Dead Cat Bounce Today
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.
Related articles »  
Endocyte, Inc. Prices Public Offering of Common Stock
WEST LAFAYETTE, Ind., March 27, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $21.00 per share.
Related articles »  
Endocyte, Inc. Closes Public Offering of Common Stock
WEST LAFAYETTE, Ind., April 2, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) announced today the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $21.00 per ...
Perilous Reversal Stock: Endocyte (ECYT)
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.
Post-Market Activity Shows Endocyte (ECYT) Down
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases.
Related articles »  
Wednesday Update: Lexmark International Inc (NYSE:LXK); Endocyte, Inc ...
Endocyte, Inc. (NASDAQ:ECYT) announced yesterday that is will offer 4.5 million of its common stock for sale through an underwritten public offering.
Related articles »  
Endocyte raises another $100M in stock offering
Endocyte Inc. raised $101.8 million in a public stock offering, the West Lafayette-based drugmaker announced last week, giving it more cash to keep developing its stable of cancer drugs.
News Recap: Celldex Therapeutics, Inc. (CLDX), Endocyte, Inc. (ECYT), Cell ...
Las Vegas, NV - April 11, 2014� (TechSonian) �Celldex Therapeutics, Inc. (CLDX) recently reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a mixture of cell lines.
Related articles »